A study published recently has shown that Velcade treatment combined with high cut-off haemodialysis (HCOD) is a potentially effective strategy in rescuing renal function and improving outcomes in newly diagnosed myeloma patients with severe renal impairment. Published in the American Journal of Hematology, the researchers found that patients (n=21) treated with Velcade and HCOD responded promptly with > 90% reduction in serum free light chains within a median of 1.4 months and achieved post-induction and best stringent complete response rates of 19% and 38% respectively. In addition, 76% of patients became dialysis independent within a median of 32 days. Further studies involving larger numbers of patients to confirm the benefits of this approach are planned.

Read full article